Sugi Predict

Sugi Predict / Compounds / SCHEMBL446842

SCHEMBL446842

SCHEMBL446842

Clc1cc2c(Cl)cccc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.46
▸ CYP2A6 P11509 3/20 0.46
▸ AHR P35869 9/20 0.45
▸ TTR P02766 3/20 0.39
▸ PSMB8 P28062 1/20 0.38
▸ NR4A2 P43354 1/20 0.37
▸ F2RL3 Q96RI0 1/20 0.36
▸ GABRP O00591 1/20 0.35
▸ GABRD O14764 1/20 0.35
▸ GABRA1 P14867 1/20 0.35
▸ GABRB1 P18505 1/20 0.35
▸ GABRG2 P18507 1/20 0.35
▸ GABRB3 P28472 1/20 0.35
▸ GABRA5 P31644 1/20 0.35
▸ GABRA3 P34903 1/20 0.35
▸ GABRA2 P47869 1/20 0.35
▸ GABRB2 P47870 1/20 0.35
▸ GABRA4 P48169 1/20 0.35
▸ GABRE P78334 1/20 0.35
▸ GABRA6 Q16445 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31326155 0.78 AHR (0.42) CYP1A2CYP2A6AHRTTRPSMB8
SCHEMBL2090794 0.78 AHR (0.42) CYP1A2CYP2A6AHRTTRPSMB8
SCHEMBL30421443 0.78 AHR (0.38) AHRTTRF2RL3GABRPGABRD
SCHEMBL8286028 0.78 AHR (0.42) CYP1A2CYP2A6AHRTTRPSMB8
SCHEMBL30538822 0.78 AHR (0.42) CYP1A2CYP2A6AHRTTRPSMB8
SCHEMBL23218380 0.78 CYP1A2 (0.42) CYP1A2CYP2A6AHRGABRPGABRD
SCHEMBL23479560 0.75 AHR (0.40) CYP1A2CYP2A6AHRTTRPSMB8
SCHEMBL25322078 0.74 AHR (0.39) CYP1A2CYP2A6AHRTTRPSMB8
SCHEMBL23479401 0.74 AHR (0.39) CYP1A2CYP2A6AHRTTRPSMB8
SCHEMBL23218772 0.74 AHR (0.35) AHRGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118666871-A Benzofuran [3,2-b ] benzofuran compound as well as preparation method and application thereof 西北工业大学 2024-09-20 — — CN claimed
CN-120136901-A Organic compound and use this organic electroluminescent device of compound 蒲城欧得新材料有限公司 2025-06-13 — — CN disclosed
CN-119661546-A Organic light-emitting compound and organic electroluminescent device thereof 西安欧得光电材料有限公司 2025-03-21 — — CN disclosed
CN-118666871-A Benzofuran [3,2-b ] benzofuran compound as well as preparation method and application thereof 西北工业大学 2024-09-20 — — CN disclosed
CN-118176196-A Benzofuro [3,2-D ] pyrimidine-2, 4-dicarbonitrile derivatives and similar compounds for use in organic electroluminescent devices 默克专利有限公司 2024-06-11 — — CN disclosed
CN-114497424-B Organic electroluminescent device and electronic device including the same 陕西莱特迈思光电材料有限公司 2024-03-19 — — CN disclosed
CN-111183204-B Organic light emitting device 株式会社LG化学 2024-03-05 — — CN disclosed
CN-111635415-B Compound, electron transport material and organic electroluminescent device 烟台显华化工科技有限公司 2023-07-25 — — CN disclosed
CN-114075216-B Organic compound, electronic component, and electronic device 陕西莱特光电材料股份有限公司 2023-06-09 — — CN disclosed
CN-110366554-B Heterocyclic compound and organic light-emitting device using the same 株式会社LG化学 2022-12-27 — — CN disclosed
CN-110366554-A Novel heterocyclic compound and organic light emitting device using the same 株式会社LG化学 2019-10-22 — — CN disclosed
CN-106661037-B Nitrogen-containing fused ring compound and organic light-emitting device using same 株式会社LG化学 2019-10-11 — — CN disclosed
CN-109476678-A Heterocyclic compound and organic light-emitting element comprising same 株式会社LG化学 2019-03-15 — — CN disclosed
CN-106661037-A Nitrogen-containing fused ring compound and organic light-emitting device using same 株式会社LG化学 2017-05-10 — — CN disclosed
EP-2613775-B1 N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2014-07-30 — — EP disclosed
US-8716285-B2 N-hydroxy-benzamids for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2014-05-06 — — US disclosed
EP-2613775-A1 NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2013-07-17 — — EP disclosed
US-20120065204-A1 NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 — — US disclosed
WO-2012031993-A1 NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 — — WO disclosed
CN-102209714-A Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIV BASEL 2011-10-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065204-A1 NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER HNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS CYP1A2 1202/4885CYP2A6 1809/4885AHR 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.